Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, real world study evaluating the apatinib-induced hypertension (HTN) in the treatment of patients with solid tumor

Next Previous
Trial Profile

A retrospective, real world study evaluating the apatinib-induced hypertension (HTN) in the treatment of patients with solid tumor

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Biliary cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 08 Jun 2021 New trial record
  • 14 Apr 2021 Results of performed in patients with gastrointestinal cancer, hepatobiliary cancer, and lung cancer, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top